We are live on
!
Find out more
DA
DSC Advisors Portfolio holdings
AUM
$11M
1-Year Est. Return
5.88%
This Fund
S&P 500
This Quarter
Est. Return
+9.3%
1 Year Est. Return
+5.88%
3 Year Est. Return
+3.18%
5 Year Est. Return
+39.43%
10 Year Est. Return
+114.64%
AUM
$129M
AUM Growth
+$31M
(+31%)
Cap. Flow
+$5.5M
Cap. Flow
% of AUM
4.25%
Top 10 Holdings %
Top 10 Hldgs %
72.18%
Holding
83
New
11
Increased
21
Reduced
34
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$5.78M |
| 2 |
Zimmer Biomet
ZBH
|
+$5.47M |
| 3 |
YARW
Yarrow Bioscience
YARW
|
+$1.73M |
| 4 |
Genius Sports
GENI
|
+$674K |
| 5 |
HYRE
HyreCar Inc. Common Stock
HYRE
|
+$594K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$5.43M |
| 2 |
eHealth
EHTH
|
+$1.66M |
| 3 |
X
US Steel
X
|
+$769K |
| 4 |
COMS
COMSovereign Holding Corp. Common Stock
COMS
|
+$725K |
| 5 |
RTX Corp
RTX
|
+$284K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 33.13% |
| 2 | Healthcare | 32.19% |
| 3 | Technology | 9.61% |
| 4 | Communication Services | 9.37% |
| 5 | Financials | 9.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
Invesco QQQ Trust
QQQ
$489B
| $39.8M | 30.74% |
+100,000
| New | +$38.6M |
|
2
CVS Health
CVS
$124B
| $11.3M | 8.76% |
109,884
-135
| -0.1% | -$12.5K |
|
3
Cencora
COR
$63.2B
| $8.64M | 6.67% |
65,000
| – | – |
|
4
Alphabet (Google) Class C
GOOG
$4.1T
| $6.66M | 5.14% |
46,000
| – | – |
|
|
5
BioMarin Pharmaceuticals
BMRN
$12.9B
| $6.18M | 4.78% |
+70,000
| New | +$5.78M |
|
|
ATH
6
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
| $5.29M | 4.09% |
63,500
| – | – |
|
|
7
Zimmer Biomet
ZBH
$18.7B
| $5.15M | 3.98% |
+41,771
| New | +$5.47M |
|
|
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.68M | 3.62% |
160,000
| – | – |
|
|
9
PUT
BioMarin Pharmaceuticals
BMRN
$12.9B
| $3.09M | 2.39% |
+35,000
| New | +$2.89M |
|
|
YARW
10
Yarrow Bioscience
YARW
$80.7M
| $2.6M | 2.01% |
2,834
+1,612
| +132% | +$1.73M |
|
|
11
Alphabet (Google) Class A
GOOGL
$4.14T
| $1.99M | 1.54% |
13,760
-360
| -3% | -$51.8K |
|
12
Microsoft
MSFT
$3.71T
| $1.99M | 1.54% |
5,915
-846
| -13% | -$274K |
|
13
Apple
AAPL
$4.67T
| $1.83M | 1.42% |
10,319
-867
| -8% | -$137K |
|
14
Meta Platforms (Facebook)
META
$1.57T
| $1.75M | 1.36% |
5,214
+443
| +9% | +$147K |
|
15
Amazon
AMZN
$2.79T
| $1.46M | 1.13% |
8,780
-200
| -2% | -$34.2K |
|
16
Berkshire Hathaway Class B
BRK.B
$1.08T
| $1.41M | 1.09% |
4,698
+683
| +17% | +$196K |
|
17
NVIDIA
NVDA
$5.56T
| $1.22M | 0.94% |
41,420
+5,430
| +15% | +$149K |
|
|
EAR
18
DELISTED
Eargo, Inc. Common Stock
EAR
| $1.17M | 0.91% |
11,500
+1,750
| +18% | +$228K |
|
|
19
eHealth
EHTH
$31.7M
| $1.15M | 0.89% |
45,000
-50,000
| -53% | -$1.66M |
|
20
Visa
V
$700B
| $1.11M | 0.86% |
5,134
+336
| +7% | +$72.1K |
|
21
Mastercard
MA
$507B
| $1.03M | 0.8% |
2,875
+65
| +2% | +$22.5K |
|
22
Accenture
ACN
$114B
| $919K | 0.71% |
2,217
-150
| -6% | -$54.7K |
|
23
Tesla
TSLA
$1.4T
| $885K | 0.68% |
2,511
-321
| -11% | -$108K |
|
24
Adobe
ADBE
$106B
| $830K | 0.64% |
1,464
+43
| +3% | +$26.9K |
|
25
Netflix
NFLX
$326B
| $825K | 0.64% |
13,700
-960
| -7% | -$61.3K |
|
Similar funds
RJTCONH
HSC
BGC
ACM
AG
RVM
JDR
KM
DSC Advisors's Q4 2021 Portfolio in Review
As of Q4 2021, DSC Advisors held 83 positions worth $129M, up 31% from $98.5M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
DSC Advisors deployed $5.5M of net new capital in Q4 2021, opening 11 new positions and adding to 21 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 70,000 shares worth $6.18M.
By sector, the portfolio is most concentrated in Miscellaneous at 33% of assets, up from 23% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was eHealth, an estimated $1.66M trimmed.
- DSC Advisors's largest Q4 2021 buy was BioMarin Pharmaceuticals: 70,000 shares worth $6.18M.
- DSC Advisors added most to Yarrow Bioscience in Q4 2021, an estimated $1.73M increase.
- DSC Advisors's biggest Q4 2021 reduction was eHealth, cutting an estimated $1.66M.
- DSC Advisors fully exited Bristol-Myers Squibb in Q4 2021, selling an estimated $5.43M.
- DSC Advisors's ten largest holdings make up 72% of its $129M portfolio in Q4 2021.
- DSC Advisors opened 11 new positions and closed 13 in Q4 2021.
- DSC Advisors's portfolio value rose 31% quarter-over-quarter to $129M.
Based on DSC Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.